Research programme: enzyme replacement therapies - Valerion Therapeutics

Next Previous
Drug Profile

Research programme: enzyme replacement therapies - Valerion Therapeutics

Alternative Names: 3E10Fab-GAA - Valerion Therapeutics; 3E10fv-MTM1 fusion protein - Valerion Therapeutics; 4s3-001; 4s3-002; 4s3-004; 4s3-005; VAL 0524; VAL-0411; VAL-0417; VAL-0620; VAL-1205

Latest Information Update: 07 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator 4s3 Bioscience
  • Developer Valerion Therapeutics
  • Class Enzymes; Proteins
  • Mechanism of Action Enzyme replacements; Protein replacements; Tumour suppressor protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Congenital structural myopathies; Myoclonic epilepsies; Myotonic dystrophy
  • Research Neurofibromatoses

Most Recent Events

  • 06 Sep 2017 Preclinical trials in Myoclonic epilepsies (Lafora disease) in USA (Intraventricular)
  • 26 Jul 2016 Early research in Myoclonic epilepsies in USA (unspecified route) (Alopexx pipelines, July 2016)
  • 26 Jul 2016 Preclinical development is ongoing for Congenital structural myopathies and Myotonic dystrophy in USA (Alopexx pipeline, July 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top